Primary Diagnosis: Diagnosis Code(s) (if known): Individual s Weight (lbs) (kg)
|
|
- Lester Heath
- 7 years ago
- Views:
Transcription
1 REVIEW REQUEST FOR Immune Globulin (Ig) Therapy Provider Data Collection Tool Based on Medical Policy DRUG & Clinical Guideline-DRUG-09 AIM Specialty Pharmacy Review (888) Policy Last Review Date: 05/07/2015 Policy Effective Date: 07/07/2015 Provider Tool Effective Date: 07/07/2015 Request Date: Initial Request Buy and Bill Individual s Name: Insurance Identification Number: Subsequent request Date of Birth: Individual s Phone Number: Primary Diagnosis: Diagnosis Code(s) (if known): Individual s Weight (lbs) (kg) Ordering Provider Name & Specialty: Provider ID Number: (if known): Office Address: Contact Name and Office Phone Number: Servicing Provider Name & Specialty (If different than Ordering Provider): Office Fax Number: Provider ID Number (if known): Office Address: Contact Name and Office Phone Number: Office Fax Number: Place of Service: Home Office Dialysis Center Outpatient Hospital Ambulatory Infusion Ambulatory Infusion Center Other: Drug Name/HCPCS Code (if known) Immune Globulin J1599 Dose to be administered: Privigen J1459 Gamma Globulin J1460 J1560 Bivigam J1556 Gammaplex J1557 (gm/kg) (mg/kg) (other) Hizentra J1559 Gamunex-C /Gammaked J1561 IGHy J3490 J7799 Gamunex-C /Gammaked J1561 Carimune J1566 Octagam J1568 Gammagard J1569 Flebogamma /Flebogamma DIF Other: J1572 When did the individual first start this drug? Duration: (Weeks) Frequency (Days, Wks, Months) Start Date For This Request: 1
2 This provider data collection tool is for medical necessity review requests for the use of immune globulin or immunoglobulin (Ig) in the treatment of: primary immunodeficiency diseases featuring low or dysfunctional antibody levels; certain inflammatory, autoimmune and other diseases featuring low antibody levels; and for removal of harmful antibodies; and blocking damage from immune cells. This tool is NOT for submission of Ig use review requests for the following: Rho (D) Immune Globulin and WinRho SD injections for the prevention or treatment of Rh incompatibility Specific hyperimmune serum globulin after exposure to Botulinum, Cytomegalovirus, Diphtheria, Hepatitis B, Measles, Rabies, Tetanus, Vaccinia, or Varicella-Zoster Any Ig product for prophylaxis against disease (for example, GamaSTAN SD [Grifols Therapeutics Inc., Research Triangle Park, NC] for hepatitis A prophylaxis) Note: Please see the following related document for additional information: DRUG Administration of Immunoglobulin as a Treatment of Recurrent Spontaneous Abortion Please check all of the following that apply to the individual: Immune Globulin (Ig) therapy for the treatment of an individual with the following: A. Antenatal Alloimmune Thrombocytopenia B. Auto-immune mucocutaneous blistering diseases (that are refractory) including: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa aquisita C. Autoimmune Neutropenia D. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Please check the following that apply): Initial Authorization: As initial trial (up to 12 weeks) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the clinical presentation is not consistent with other polyneuropathies (for example, IgM neuropathy, hereditary neuropathy, diabetic neuropathy) (Please check the following that apply): Proximal muscle weakness or sensory dysfunction caused by neuropathy and nerve conduction studies (NCS) confirm there is electrodiagnostic evidence of demyelinating neuropathy in at least 2 limbs Distal muscle weakness and results of diagnostic testing meet a recognized set of diagnostic criteria as established by the American Academy of Neurology (AAN), or Inflammatory Neuropathy Cause and Treatment (INTAC). (If checked, please indicate which criteria used and which diagnostic tests meet): Reauthorization: Clinically significant improvement in neurological symptoms is documented on physical examination. (If checked, please note improvements): Has been on treatment for less than 1 year Has been on treatment for at least 1 year and continued need is demonstrated by documentation that attempts on an annual basis to titrate the dose or the interval of therapy result in worsening symptoms. (If checked, please document dosage change and results): E. Dermatomyositis refractory to corticosteroid therapy (IVIG will be used as second line treatment after corticosteroid therapy failed) F. Eaton-Lambert Myasthenic Syndrome 2
3 G. Guillain-Barre Syndrome (acute demyelinating polyneuropathy) as an alternative to plasma exchange H. Human immunodeficiency virus (HIV) infected pediatric individual - prevention of opportunistic bacterial infections I. Hyperimmunoglobulinemia E syndrome (HIE) treatment J. Hypogammaglobulinemia and recurrent bacterial infections associated with B-Cell Chronic Lymphocytic Leukemia (CLL) (Please check the following that apply): Documented history of recurrent bacterial infection or an active infection not responding to antimicrobial therapy Documented total IgG is less than 500 mg/dl K. IgG sub-class deficiency (IgG1, IgG2, IgG3, IgG4) (Please check the following that apply): One or more serum IgG subclasses are below the lower limit of the age adjusted laboratory reference range or are more than two standard deviations below the age adjusted mean History of recurrent sinopulmonary infections requiring antibiotic therapy There is documentation of a lack of, or inadequate response to, immunization (for example, but not limited to pneumococcal antigen) L. Immune thrombocytopenia (idiopathic thrombocytopenic purpura (ITP) (Please check the following that apply): Symptomatic thrombocytopenia (for example, but not limited to hematuria, petechiae, bruising, gastrointestinal bleeding, gingival bleeding) Platelet count less than 20,000 per microliter (mcl) (adult) Platelet count less than 30,000 per mcl (microliter) (child) M. Kawasaki Syndrome (Please check the following that apply): Within 10 days of onset of symptoms Treatment planned for no more than 5 days N. Multifocal Motor Neuropathy (MMN) (Please check the following that apply): Initial Authorization: Initial trial (up to 4 weeks) Asymmetric weakness that predominately affects distal muscles (without upper motor neuron signs) and nerve conduction studies confirm a demyelinating neuropathy is present (conduction block, slowing, or abnormal temporal dispersion in at least one nerve) Clinical history and exam do not suggest upper motor neuron disease (no bulbar weakness, no upper motor neuron signs) Labs show GM-1 antibody titers are elevated. (If checked, please document GM-1 antibody titer): Clinical presentation suggests MMN but diagnosis remains uncertain following initial exam and electrodiagnostic testing Reauthorization: Continued use after initial trial Clinical results documented an improvement in strength and function within 3 weeks of the start of the infusion period. (If checked, please note improvements): Has been on treatment for less than 1 year Has been on treatment for at least 1 year and continued need is demonstrated by documentation that attempts on an annual basis to titrate the dose or the interval of therapy result in worsening symptoms. (If checked, please document dosage change and results): 3
4 O. Myasthenia Gravis which is severe and refractory to standard therapy P. Neonates - To prevent infections in high-risk, preterm, low birth weight Q. Parvovirus B19 chronic infection and severe anemia associated with bone marrow suppression R. Severe Polymyositis when other treatments have been unsuccessful, intolerable, or are contraindicated (If checked, please list previous treatments and results): S. Primary humoral immunodeficiency common Variable Immunodeficiency (CVID) (please check all that apply): Individual has a history of recurrent sinopulmonary infections requiring antibiotic therapy There is a lack of, or inadequate response to immunization (for example, but not limited to tetanus or pneumococcal antigen) There is no evidence of renal (nephrotic syndrome) and gastrointestinal (for example protein losing enteropathy, PLE) as causes of hypogammaglobulinemia The initial, pre-treatment total serum IgG is below the lower limit of the age adjusted laboratory reference range, or more than two standard deviations below the age adjusted mean T. Primary humoral immunodeficiency - Other (for example, congenital agammaglobulinemia, X-linked immunodeficiency, severe combined immunodeficiency [SCID], or Wiskott-Aldrich syndrome [WAS]) when (please check all that apply): There is no evidence of renal (nephrotic syndrome) and gastrointestinal (for example, protein losing enteropathy) as causes of hypogammaglobulinemia The initial, pre-treatment total serum IgG is below the lower limit of the age adjusted laboratory reference range, or more than two standard deviations below the age adjusted mean U. Stiff-person syndrome not controlled by other therapies V. Toxic shock syndrome caused by staphylococcal or streptococcal organisms refractory to several hours of aggressive therapy W. Transplant Hematopoietic stem cell transplant (Please check the following that apply): Allogeneic bone marrow transplant (BMT) recipient in the first 100 days after transplantation To reduce risk of graft-versus-host disease associated with interstitial pneumonia (infectious or idiopathic) and infections (cytomegalovirus infections, varicella-zoster virus infection, and recurrent bacterial infection) Secondary hypoglobulinemia in an immunosuppressed individual (for example, status post bone marrow transplant) Documented total IgG less than 500 mg/dl Solid organ transplant (Please check the following that apply): Prior to a medically necessary solid organ transplantation For suppression of panel reactive anti-hla antibodies and individuals with high panel reactive antibody (PRA) levels to human leukocyte antigens (HLA) Solid organ transplant recipients at risk for CMV 4
5 X. Other Indications To prevent recurrent spontaneous abortions Alzheimer s disease Immune optic neuropathy Multiple sclerosis Other: This request is being submitted: Pre-Claim Post Claim. If checked, please attach the claim or indicate the claim number I attest the information provided is true and accurate to the best of my knowledge. I understand that the health plan or its designee may perform a routine audit and request the medical documentation to verify the accuracy of the information reported on this form. Name & Title of Provider or Provider Representative Completing Form Date & attestation (Please Print)* *The attestation fields must be completed by a provider or provider representative in order for the tool to be accepted Anthem UM Services, Inc., a separate company, is the licensed utilization review agent that performs utilization management services on behalf of your health benefit plan or the administrator of your health benefit plan. 5
Gateway Health SM Non-Formulary Prior Authorization Criteria Intravenous Immune Globulin (IVIG)
Gateway Health SM Non-Formulary Prior Authorization Criteria Intravenous Immune Globulin (IVIG) Coverage is provided in the following situations: PARP Approved 6/2015 Coverage is provided for Primary Immunodeficiency
More informationImmune Globulins. Subcutaneous Immune Globulin: Hizentra and HyQvia
Immune Globulins Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen Subcutaneous Immune Globulin:
More informationIVIG (Intravenous Immune Globulin) SCIG (Subcutaneous Immune Globulin)
Phone: (800) 244-6224 Fax: (855) 840-1678 IVIG (Intravenous Immune Globulin) SCIG (Subcutaneous Immune Globulin) Notice: Please be sure to complete this form in its entirety. Missing information makes
More informationCANADA IS ONE of the world s highest per
Evidence-Based Guidelines on the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions Paula Robinson, David Anderson, Melissa Brouwers, Thomas E. Feasby, and Heather Hume, on behalf
More informationLCD for Intravenous Immune Globulin (L29205)
LCD for Intravenous Immune Globulin (L29205) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29205 LCD Information
More informationImmune Globulin (IVIG and SCIG)
Immune Globulin (IVIG and SCIG) DRUG POLICY Policy Number: 2015D0035R Effective Date: 10/1/2015 Table of Contents Page COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 14 BACKGROUND... 14 CLINICAL EVIDENCE...
More informationTransient Hypogammaglobulinemia of Infancy. Chapter 7
Transient Hypogammaglobulinemia of Infancy Chapter 7 An unborn baby makes no IgG (antibody) and only slowly starts producing it after birth. However, starting at about the sixth month of pregnancy, the
More informationGuideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)
22 July 2010 EMA/CHMP/BPWP/94033/2007 rev. 2 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: immune_globulin_therapy 07/1994 2/2015 2/2016 2/2015 Description of Procedure or Service Human immune globulin
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationHuman Normal Immunoglobulin Solution for Intravenous Infusion.
CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM is available in single use bottles of 20 ml, 50 ml, 100 ml and 200 ml. OCTAGAM contains
More informationCHF INCLEN ADVAC 2011. Vaccination in Special Situations: Break-out sessions. Group B
CHF INCLEN ADVAC 2011 Vaccination in Special Situations: Break-out sessions Group B 1 Group B. Moderator: Dr. Rohit Agrawal Expert: Dr. Walter Orenstien 2 Learning objectives: What are the special situation
More informationIntravenous Immunoglobulin in Neurological disorders
Intravenous Immunoglobulin in Neurological disorders Exceptional healthcare, personally delivered What is Intravenous Immunoglobulin (IVIg)? Intravenous immunoglobulin (IVIg) is a blood product that combines
More informationLocal Coverage Determination (LCD): Immune Globulins (L34771)
Local Coverage Determination (LCD): Immune Globulins (L34771) Contractor Information Contractor Name Wisconsin Physicians Service Insurance Corporation LCD Information Document Information LCD ID L34771
More informationProtein electrophoresis is used to categorize globulins into the following four categories:
Globulin Globulin is one of the two types of serum proteins, the other being albumin. This generic term encompasses a heterogeneous series of families of proteins, with larger molecules and less soluble
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationIMMUNIZATION IN SPECIAL SITUATIONS
143 IMMUNIZATION IN SPECIAL SITUATIONS Immunization in preterm/low birth weight infants In principle, all vaccines may be administered as per schedule according to the chronological age irrespective of
More informationSevere Combined Immune Deficiency (SCID)
Severe Combined Immune Deficiency (SCID) ASCIA EDUCATION RESOURCES (AER) PATIENT INFORMATION Severe combined immune deficiency (SCID) is the most serious form of primary immune deficiency and is usually
More informationMultifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD
Multifocal Motor Neuropathy Jonathan Katz, MD Richard Lewis, MD What is Multifocal Motor Neuropathy? Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by
More informationFURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES
FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES Dr Alison Jones Great Ormond Street Hospital for Children NHS Trust London WC1N 3JH United Kingdom
More informationCo-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
More informationALBERTA BLOOD AND MARROW TRANSPLANT PROGRAM NEW GUIDELINES FOR THE IMMUNIZATION OF HEMATOPOIETIC STEM CELL TRANSPLANT(HSCT) RECIPIENTS JULY 11, 2013
ALBERTA BLOOD AND MARROW TRANSPLANT PROGRAM NEW GUIDELINES FOR THE IMMUNIZATION OF HEMATOPOIETIC STEM CELL TRANSPLANT(HSCT) RECIPIENTS JULY 11, 2013 RE-IMMUNIZATION IS IMPORTANT! There should be no assumptions
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationSARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES
SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES TABLE OF CONTENTS SUBJECT PAGE ADULT CRITERIA Red Blood Cells/Autologous 2 Washed Red Blood Cells 2 Cryoprecipitate
More informationCytomegalovirus (HHV5/CMV) Roseolovirus (HHV6 & 7)
Betaherpesvirinae Cytomegalovirus (HHV5/CMV) Roseolovirus (HHV6 & 7) CYTOMEGALOVIRUS CMV is thought to be amongst the oldest type of herpesvirus in evolutionary terms. CMV is the prototype of beta-herpesviruses
More information3nd Biennial Contemporary Clinical Neurophysiological Symposium October 12, 2013 Fundamentals of NCS and NMJ Testing
3nd Biennial Contemporary Clinical Neurophysiological Symposium October 12, 2013 Fundamentals of NCS and NMJ Testing Peter D. Donofrio, M.D. Professor of Neurology Vanderbilt University Medical Center
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationEMG and the Electrodiagnostic Consultation for the Family Physician
EMG and the Electrodiagnostic Consultation for the Family Physician Stephanie Kopey, D.O., P.T. 9/27/15 The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Marketing Committee
More informationSpecific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology
Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology INTRODUCTION 2009 A university wishing to have an accredited program in Pediatric Hematology/Oncology must also
More informationCIDP Chronic Inflammatory Demyelinating Polyneuropathy. A publication of the GBS/CIDP Foundation International
CIDP Chronic Inflammatory Demyelinating Polyneuropathy A publication of the GBS/CIDP Foundation International A special acknowledgement to Dr. Carol Lee Koski, member of the GBS/CIDP Medical Advisory Board
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationCore Topic 2. The immune system and how vaccines work
Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain
More informationSelective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org
Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org About this booklet This booklet provides information on selective IgA deficiency (sigad). It has been produced by the PID UK
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary
More informationClinical Guidelines for Immunoglobulin Use (Second Edition)
DH INFORMATION READER BOX Policy Estates HR / Workforce Commissioning Management IM & T Planning / Finance Performance Clinical Social Care / Partnership Document Purpose Best Practice Guidance Gateway
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationWhat is HIV? What is AIDS? The HIV pandemic HIV transmission Window period Stages of HIV infection
Module 1 Overview of HIV Infection Purpose Pre-requisite Modules Learning Objectives To provide you with the basic terms and concepts related to HIV infection. None At the end of this module, you will
More informationINTRODUCTION. Key words: Immunoglobulin, IGIV, intravenous immunoglobulin, transfusion, adverse events, primary immunodeficiency, immunomodulation,
Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology Jordan S. Orange,
More informationAppendix E-- The CDC s Current and Proposed Classification System for HIV Infection
Appendix E-- The CDC s Current and Proposed Classification System for HIV Infection The Centers for Disease Control (CDC) has developed a classification system for human immunodeficiency virus (HIV) infection
More informationChapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not
More informationRe: RIN 0906-AA94, Exclusion of Orphan Drugs for Certain Covered Entities Under the 340B Program
July 19, 2011 Reference No. FASC11042 CDR Krista Pedley Director, Office of Pharmacy Affairs Health Systems Bureau Health Resources and Services Administration 5600 Fishers Lane Parklawn Building, Room
More informationThymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.
Thymus Cancer Introduction Thymus cancer is a rare cancer. It starts in the small organ that lies in the upper chest under the breastbone. The thymus makes white blood cells that protect the body against
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationIg VENA 50 g/l Solution for infusion Human normal immunoglobulin (IVIg) for intravenous use
PACKAGE LEAFLET: INFORMATION FOR THE USER Ig VENA 50 g/l Solution for infusion Human normal immunoglobulin (IVIg) for intravenous use Read all of this leaflet carefully before you start using this medicine.
More informationQUICK REFERENCE TO BLOOD BANK TESTING
QUICK REFERENCE TO BLOOD BANK TESTING All Blood bank Tests are performed on demand 24 hours a day, 7 days a week. Feto/Maternal Bleed Quantitation estimates will be available within 4 hours of blood bank
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationSystemic Lupus Erythematosus
Harvard-MIT Division of Health Sciences and Technology HST.021: Musculoskeletal Pathophysiology, IAP 2006 Course Director: Dr. Dwight R. Robinson Systemic Lupus Erythematosus A multi-system autoimmune
More informationCPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD
The blood and marrow transplant field has 15 dedicated CPT codes. These CPT codes can be categorized into three groups: 1. Collection Codes 2. Cell Processing Codes 3. Cell Infusion Codes Collection Codes
More informationWhy use passive immunity?
Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:
More informationHematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095
Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095 CS 6.4 DIAGNOSIS AND MANAGEMENT OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE Location:
More informationImmune-Mediated Low Platelet or Thrombocyte Count
rally is Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Immune-Mediated Low Platelet or Thrombocyte Count (Thrombocytopenia)
More informationacquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare
Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated
More informationLEMTRADA REMS Education Program for Prescribers
For Prescribers LEMTRADA REMS Education Program for Prescribers This education program includes information about: The LEMTRADA REMS Program requirements Serious risks of autoimmune conditions, infusion
More informationF r e q u e n t l y A s k e d Q u e s t i o n s
Myasthenia Gravis Q: What is myasthenia gravis (MG)? A: Myasthenia gravis (meye-uhss- THEEN-ee-uh GRAV uhss) (MG) is an autoimmune disease that weakens the muscles. The name comes from Greek and Latin
More informationBackground: 1) Does your center have effective ways of collecting data from multiple sources to submit to multiple organizations?
University of Michigan Best Practices Pam James, MS CCRP Administrative Manager, Data Management Bone Marrow Transplant, Hematologic Malignancies & NCCN Background: The data management team at the University
More informationAutoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system
More informationZika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases
Zika Virus Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases What is the incubation period for Zika virus infection? Unknown but likely to be several
More informationEffective Treatment of Lyme Borreliosis with Pentacyclic Alkaloid Uncaria tomentosa (TOA-free Cat s Claw)
Effective Treatment of Lyme Borreliosis with Pentacyclic Alkaloid Uncaria tomentosa (TOA-free Cat s Claw) Executive Summary Introduction In a six-month prospective cohort study designed to compare the
More informationMultiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.
Multiple Myeloma Introduction Multiple myeloma is a type of cancer that affects white blood cells. Each year, thousands of people find out that they have multiple myeloma. This reference summary will help
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationThe Practice of Travel Health for Pharmacists
The Practice of Travel Health for Pharmacists Joint California Pharmacists Association and California Society of Health- System Pharmacists Sub- Committee on SB493 Travel Medicine Provision Jeff Goad (Chair)
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationOn April 4, a group of physicians at the 37th annual
By Ronale Tucker Rhodes, MS Better gene sampling and newer transplant regimens are making stem cell transplantation possible for a host of disease states that previously were rarely considered for this
More informationAsthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System
1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID
More informationINTRAVENOUS IMMUNOGLOBULINS IN THE THERAPY OF IMMUNE-MEDIATED HEMATOLOGIC DISORDERS Susan G. Hackner, BVSc.MRCVS.DACVIM. DACVECC.
INTRAVENOUS IMMUNOGLOBULINS IN THE THERAPY OF IMMUNE-MEDIATED HEMATOLOGIC DISORDERS Susan G. Hackner, BVSc.MRCVS.DACVIM. DACVECC. Intravenous immunoglobulin (IVIG) is used for the treatment of numerous
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationBOTOX Injection (Onabotulinumtoxin A) for Migraine Headaches [Preauthorization Required]
BOTOX Injection (Onabotulinumtoxin A) for Migraine Headaches [Preauthorization Required] Medical Policy: MP-RX-01-11 Original Effective Date: March 24, 2011 Reviewed: Revised: This policy applies to products
More informationTransplant Options When You Don t Have a Good Match
Transplant Options When You Don t Have a Good Match 1 Transplant Options When You Don t Have a Good Match Being told you need a transplant may bring about many feelings, including anxiety and uncertainty.
More informationStem Cell Background Paper
Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,
More informationCMV: Your questions answered
The basics about the virus CMV: Your questions answered What is CMV? CMV, or Cytomegalovirus, is a common virus that can infect people of all ages. Once CMV is in a person s body, it stays there for life.
More informationCord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral
More informationSMF Awareness Seminar 2014
SMF Awareness Seminar 2014 Clinical Evaluation for In Vitro Diagnostic Medical Devices Dr Jiang Naxin Health Sciences Authority Medical Device Branch 1 In vitro diagnostic product means Definition of IVD
More informationDetermining Donor Eligibility Blood Donor vs. Stem Cell Donor. Wanda Koetz, RN, HPC Clinical Nurse Lead, Memorial Blood Centers ASFA - May 7, 2015
Determining Donor Eligibility Blood Donor vs. Stem Cell Donor Wanda Koetz, RN, HPC Clinical Nurse Lead, Memorial Blood Centers ASFA - May 7, 2015 Objectives The learner will be able to: Define donor eligibility
More informationDisclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
More informationParvovirus B19 Infection in Pregnancy
Parvovirus B19 Infection in Pregnancy Information Pack Parvovirus B19 Infection in Pregnancy Information Booklet CONTENTS: THE VIRUS page 3 CLINICAL MANIFESTATIONS page 6 DIAGNOSIS page 8 PATIENT MANAGEMENT
More informationRecommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2014
Recommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2014 This schedule includes recommendations in effect as of January 1, 2014. Any dose not administered at the recommended
More information2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
More informationPediatric Latent TB Diagnosis and Treatment
Date Updated: April 2015 Guidelines Reviewed: 1. CDC Latent TB Guidelines 2. Harborview Pediatric Clinic Latent TB Management, 2010 3. Pediatric Associates Latent TB Guidelines, 2013 4. Seattle Children
More informationSTUDY ABROAD HEALTH CLEARANCE INSTRUCTIONS. For Students
STUDY ABROAD HEALTH CLEARANCE INSTRUCTIONS For Students 1. Fill out the student sections on pages 1, 2 and 5. Take all the pages with you to your physical exam appointment. 2. During your physical exam,
More informationThe Immune System and Disease
Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Nanogam 50 mg/ml solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (IVIg) 1 ml
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationDelaware. Downloaded 01/2011
Delaware Downloaded 01/2011 3.0 CNA Training Program Requirements 3.3 Curriculum Content 3.3.2 Environmental Needs Of The Resident Key Concepts: Introduces the nursing assistant to the need to keep residents
More informationImmunity and how vaccines work
1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms
More informationSubcutaneous Immunoglobulin Replacement Therapy with Hizentra, the First 20% SCIG Preparation: a Practical Approach
SUMMARY SLIDE Subcutaneous Immunoglobulin Replacement Therapy with Hizentra, the First 20% SCIG Preparation: a Practical Approach Benefits of SCIG administration compared with IVIG include: avoidance of
More informationThe ANA Test: All You Need to Know Department of Family and Community Medicine Family Medicine Update April 25, 2014
The ANA Test: All You Need to Know Department of Family and Community Medicine Family Medicine Update April 25, 2014 Celso R. Velázquez MD Division of Rheumatology University of Missouri velazquezc@health.missouri.edu
More informationLCD for Viral Hepatitis Serology Tests
LCD for Viral Hepatitis Serology Tests Applicable CPT Code(s): 86692 Antibody; Hepatitis, Delta Agent 86704 Hepatitis B Core Antibody (HBcAb); Total 86705 Hepatitis B Core Antibody (HBcAb); IgM Antibody
More informationImmunomodulatory Effects of Intravenous Immunoglobulins as a Treatment for Autoimmune Diseases, Cancer, and Recurrent Pregnancy Loss
Immunomodulatory Effects of Intravenous Immunoglobulins as a Treatment for Diseases, Cancer, and Recurrent Pregnancy Loss TAL SAPIR, a,b MIRI BLANK, a,c AND YEHUDA SHOENFELD a,c,d a Department of Internal
More informationGRANIX (tbo-filgrastim)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil
More informationSummary of the risk management plan (RMP) for Accofil (filgrastim)
EMA/475472/2014 Summary of the risk management plan (RMP) for Accofil (filgrastim) This is a summary of the risk management plan (RMP) for Accofil, which details the measures to be taken in order to ensure
More informationEvaluation of the Patient with Suspected Platelet Refractory State
Evaluation of the Patient with Suspected Platelet Refractory State NOTE: While evaluating the patient for suspected immune refractory state provide ABO matched platelets if available. 1. Determine if the
More information